BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hajduch E, Lachkar F, Ferré P, Foufelle F. Roles of Ceramides in Non-Alcoholic Fatty Liver Disease. J Clin Med 2021;10:792. [PMID: 33669443 DOI: 10.3390/jcm10040792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 O'Farrell M, Duke G, Crowley R, Buckley D, Martins EB, Bhattacharya D, Friedman SL, Kemble G. FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models. Sci Rep 2022;12:15661. [PMID: 36123383 DOI: 10.1038/s41598-022-19459-z] [Reference Citation Analysis]
2 Höring M, Peschel G, Grimm J, Krautbauer S, Müller M, Weigand K, Liebisch G, Buechler C. Serum Ceramide Species Are Associated with Liver Cirrhosis and Viral Genotype in Patients with Hepatitis C Infection. IJMS 2022;23:9806. [DOI: 10.3390/ijms23179806] [Reference Citation Analysis]
3 Jackson KG, Way GW, Zhou H. Bile acids and sphingolipids in non-alcoholic fatty liver disease. Chin Med J (Engl) 2022. [PMID: 35788089 DOI: 10.1097/CM9.0000000000002156] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bathish B, Robertson H, Dillon JF, Dinkova-Kostova AT, Hayes JD. Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2. Free Radic Biol Med 2022;188:221-61. [PMID: 35728768 DOI: 10.1016/j.freeradbiomed.2022.06.226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Torres S, Segalés P, García-Ruiz C, Fernández-Checa JC. Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. Cells 2022;11:1475. [PMID: 35563780 DOI: 10.3390/cells11091475] [Reference Citation Analysis]
6 Song Q, Liu H, Zhang Y, Qiao C, Ge S. Lipidomics Revealed Alteration of the Sphingolipid Metabolism in the Liver of Nonalcoholic Steatohepatitis Mice Treated with Scoparone. ACS Omega 2022;7:14121-7. [PMID: 35559132 DOI: 10.1021/acsomega.2c00693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Fridén M, Rosqvist F, Ahlström H, Niessen HG, Schultheis C, Hockings P, Hulthe J, Gummesson A, Wanders A, Rorsman F, Risérus U, Vessby J. Hepatic Unsaturated Fatty Acids Are Linked to Lower Degree of Fibrosis in Non-alcoholic Fatty Liver Disease. Front Med (Lausanne) 2021;8:814951. [PMID: 35083257 DOI: 10.3389/fmed.2021.814951] [Reference Citation Analysis]
8 Gnoni A, Di Chiara Stanca B, Giannotti L, Gnoni GV, Siculella L, Damiano F. Quercetin Reduces Lipid Accumulation in a Cell Model of NAFLD by Inhibiting De Novo Fatty Acid Synthesis through the Acetyl-CoA Carboxylase 1/AMPK/PP2A Axis. Int J Mol Sci 2022;23:1044. [PMID: 35162967 DOI: 10.3390/ijms23031044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
9 Li M, Rajani C, Zheng X, Jia W. The microbial metabolome in metabolic‐associated fatty liver disease. Journal of Gastroenterology and Hepatology. [DOI: 10.1111/jgh.15746] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Sztolsztener K, Konstantynowicz-Nowicka K, Harasim-Symbor E, Chabowski A. Time-Dependent Changes in Hepatic Sphingolipid Accumulation and PI3K/Akt/mTOR Signaling Pathway in a Rat Model of NAFLD. Int J Mol Sci 2021;22:12478. [PMID: 34830360 DOI: 10.3390/ijms222212478] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Tanase DM, Gosav EM, Petrov D, Jucan AE, Lacatusu CM, Floria M, Tarniceriu CC, Costea CF, Ciocoiu M, Rezus C. Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets. Diagnostics (Basel) 2021;11:2053. [PMID: 34829402 DOI: 10.3390/diagnostics11112053] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Zhai R, Feng L, Zhang Y, Liu W, Li S, Hu Z. Combined Transcriptomic and Lipidomic Analysis Reveals Dysregulated Genes Expression and Lipid Metabolism Profiles in the Early Stage of Fatty Liver Disease in Rats. Front Nutr 2021;8:733197. [PMID: 34604283 DOI: 10.3389/fnut.2021.733197] [Reference Citation Analysis]
13 Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab 2021;50:101238. [PMID: 33892169 DOI: 10.1016/j.molmet.2021.101238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 35] [Article Influence: 1.0] [Reference Citation Analysis]